Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
6.06
-0.05 (-0.82%)
At close: Oct 3, 2024, 4:00 PM
6.11
+0.05 (0.83%)
After-hours: Oct 3, 2024, 7:00 PM EDT

Recursion Pharmaceuticals Revenue

Recursion Pharmaceuticals had revenue of $14.42M in the quarter ending June 30, 2024, with 30.86% growth. This brings the company's revenue in the last twelve months to $49.64M, down -0.70% year-over-year. In the year 2023, Recursion Pharmaceuticals had annual revenue of $44.58M with 11.88% growth.

Revenue (ttm)
$49.64M
Revenue Growth
-0.70%
P/S Ratio
28.06
Revenue / Employee
$99,270
Employees
500
Market Cap
1.70B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202344.58M4.73M11.88%
Dec 31, 202239.84M29.67M291.46%
Dec 31, 202110.18M6.22M156.89%
Dec 31, 20203.96M1.64M70.85%
Dec 31, 20192.32M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Fortrea Holdings 3.01B
Supernus Pharmaceuticals 630.16M
NovoCure 549.96M
Kiniksa Pharmaceuticals International, 338.93M
STAAR Surgical Company 332.94M
CareDx 297.08M
MannKind 248.37M
Arvinas 93.30M
Revenue Rankings